Truveris Stock
Truveris is a technology company driving transparency, access and lower costs across the prescription drug ecosystem.
Sign up today and learn more about Truveris Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Truveris Stock
Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market access challenges. Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital.
Funding History
February 2011 | $3.8M |
---|---|
February 2012 | $10.0M |
June 2014 | $12.8M |
March 2016 | $2.5M |
September 2017 | $25.0M |
Management
CEO
Jeff Eberle
Chief Pharmacy Officer
Alysha Fluno
CMO
Jeff Ignaszak
Chief Financial Officer
Michael Facendola
Press
businesswire - Jun, 15 2018
Truveris Expands Audit Capabilities with Launch of TruAudit™cnbc - Mar, 27 2018
Faisal Mushtaqbusinesswire - Mar, 21 2018
Truveris Appoints Sally Welborn, former head of Walmart Global Benefits to Board of Directors